ORPHA:300605
Juvenile amyotrophic lateral sclerosis
Also known as: JALS · Juvenile Charcot disease · Juvenile Lou Gehrig disease
Publications
370
78.5th percentile
Trials
0
Interventional, condition-specific
Researchers
1,578
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare motor neuron disease characterized by onset before 25 years of age of upper and/or lower motor neuron degeneration, leading to bulbar and limb motor impairment, with marked clinical and genetic heterogeneity.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017593
- UMLS:C3468114
Additional Mondo synonyms (2)
juvenile Charcot disease · juvenile Lou Gehrig disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
370 matched papers (198 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 676 for broader category amyotrophic lateral sclerosis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
370
370 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
370 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
198 in the last 10 years · medium confidence · 78.5th percentile (publications denominator)
Phrase hits: 370 · MeSH hits: 0
Who's working on it?
1,578
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Chiò A6 papers · 2021
Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy; Città della Salute e della Scienza University Hospital, Turin, Italy.
Papers in Europe PMC - 02Muntoni F5 papers · 2024
From the MRC Centre for Neuromuscular Diseases (A.H., P.J.T., M.L., M.G.H., J.C.B., H.H., M.M.R.), UCL Institute of Neurology, Queen Square, London, UK; Department of Human Genetics and Hussman Institute for Human Genomics (M.A.G., S.Z.), Miller School of Medicine, University of Miami; The Genesis Project Foundation (M.A.G.), Miami, FL; The Dubowitz Neuromuscular Centre (F.M., A.Y.M.), UCL Institute of Child Health, London; and Department of Clinical Neurophysiology (J.C.B.), Norfolk and Norwich University Hospital, Norwich, UK.
Papers in Europe PMC - 03Brown RH4 papers · 2021
Department of Neurology, University of Massachusetts Medical School, Worcester.
Papers in Europe PMC - 04Calvo A4 papers · 2021
'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Papers in Europe PMC - 05Chen L4 papers · 2024
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Papers in Europe PMC - 06Chen S4 papers · 2025
Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China.
Papers in Europe PMC - 07Chia R4 papers · 2021
Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. Electronic address: ruth.chia@nih.gov.
Papers in Europe PMC - 08Conte A4 papers · 2021
Adult NEMO Clinical Center, Complex Operational Unit of Neurology, Department of Aging, Neurological, Orthopedic and Head-Neck Sciences, A. Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.
Papers in Europe PMC - 09Landers JE4 papers · 2021
Department of Neurology, University of Massachusetts Medical School, Worcester.
Papers in Europe PMC - 10Lattante S4 papers · 2021
Section of Genomic Medicine, Department of Life Sciences and Public Health, Faculty of Medicine and Surgery, Catholic University of the Sacred Heart, 00168 Roma, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 676 trials are registered for amyotrophic lateral sclerosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
676 interventional trials matched amyotrophic lateral sclerosis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: amyotrophic lateral sclerosis
676
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04302870·RECRUITING·Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
Conditions: Motor Neuron Disease, Amyotrophic Lateral Sclerosis·Matched via name phrase
- NCT06607900·NOT YET RECRUITING·hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
Conditions: Alzheimer Disease · Parkinson Disease · Lewy Body Dementia · Multiple System Atrophy·Matched via name phrase
- NCT06782724·RECRUITING·Psilocybin Therapy for Psychological Distress in Palliative Patients
Conditions: COPD (Chronic Obstructive Pulmonary Disease) · ALS (Amyotrophic Lateral Sclerosis) · MS (Multiple Sclerosis) · Major Depressive Disorder (MDD)·Matched via name phrase
- NCT06513546·NOT YET RECRUITING·A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients
Conditions: Amyotrophic Lateral Sclerosis · ALS·Matched via name phrase
- NCT07006571·RECRUITING·At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis
Conditions: ALS · ALS (Amyotrophic Lateral Sclerosis)·Matched via name phrase
- NCT06671236·RECRUITING·Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
Conditions: Amyotrophic Lateral Sclerosis (ALS)·Matched via name phrase
- NCT06849609·RECRUITING·A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
Conditions: Amyotrophic Lateral Sclerosis (ALS)·Matched via name phrase
- NCT07407725·RECRUITING·Clinical Outcome Assessment for AT & BCI
Conditions: Spinal Cord Injury · ALS (Amyotrophic Lateral Sclerosis)·Matched via name phrase
- NCT07454733·NOT YET RECRUITING·Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
Conditions: Amyotrophic Lateral Sclerosis (ALS)·Matched via name phrase
- NCT07312240·RECRUITING·LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS
Conditions: Amyotrophic Lateral Sclerosis·Matched via name phrase
- NCT06968468·NOT YET RECRUITING·Resiliency Intervention for Patients With ALS and Their Care-Partners
Conditions: Amyotrophic Lateral Sclerosis (ALS) · Emotional Distress·Matched via name phrase
- NCT07093268·NOT YET RECRUITING·Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
Conditions: Amyotrophic Lateral Sclerosis · Motor Neuron Disease·Matched via name phrase
- NCT07357428·RECRUITING·Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)
Conditions: Amyotrophic Lateral Sclerosis · Neuromuscular Disease · Stroke · Tetraplegia/Tetraparesis·Matched via name phrase
- NCT06973629·NOT YET RECRUITING·Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Conditions: Amyotrophic Lateral Sclerosis (ALS) · Amyotrophic Lateral Sclerosis·Matched via name phrase
- NCT07533903·RECRUITING·Functional Outcomes and Control Using Synchron BCI - Australia
Conditions: Neurologic Disorder · Neurologic Diseases · MND (Motor Neurone DIsease) · Motor Neuron Disease·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Juvenile amyotrophic lateral sclerosis" OR "Juvenile Charcot disease" OR "Juvenile Lou Gehrig disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Juvenile amyotrophic lateral sclerosis" OR "Juvenile Charcot disease" OR "Juvenile Lou Gehrig disease"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"amyotrophic lateral sclerosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: JALS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:42:57.586Z
